Sign up USA
Proactive Investors - Run By Investors For Investors

Valeant Pharma says U.S. FDA has more questions about ringworm treatment

Valeant Pharma says U.S. FDA has more questions about ringworm treatment

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) says that the U.S. FDA has remaining questions about the company's new drug application for efinaconazole - a drug designed for the treatment of onychomycosis, more commonly known as ringworm.

The company said Tuesday it has received a complete response letter from the U.S. health regulator, which is issued when questions remain that preclude the approval of the new drug application in its current form. 

The questions relate to the chemistry, manufacturing and controls areas of the container closure apparatus, the company said, as no efficacy or safety issues were raised. 

As a result, Valeant said it believes these concerns can be addressed and is working on respond to the FDA as soon as possible, remaining comitted to bringing efinaconazole to market. 

The news follows the company's announcement yesterday, when it said it had inked an $8.7 billion cash deal to take over Bausch & Lomb Holdings Inc., the eye-care company owned by New York-based Warburg Pincus LLC. 

The acquisition positions Valeant to capitalize on growing eye health trends driven by an aging patient population, an increased rate of diabetes and demand from emerging markets.

Shares of Valeant in Toronto were lately down by 0.6 per cent at $95.25, after climbing sharply on Monday after news of the acquisition. In New York, shares of Valeant were up by more than 8 per cent, as U.S. markets played catch-up after being closed Monday for the Memorial Day holiday.

Valeant develops, manufactures and markets a range of pharamceutical products, primarily in the areas of dermatology, neurology and branded generics. 



Register here to be notified of future VRX Company articles
View full VRX profile View Profile

Valeant Pharmaceuticals Timeline

Article
February 28 2017

Related Articles

Cells
May 17 2017
Revenues are on the rise and the group’s efforts to bring in new business is delivering.
shutterstock_127456451.jpg
March 30 2017
PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales in 2016
ventripoint_device.png
Wed
The device can give accurate and rapid volumetric information about all four chambers of the heart
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use